Methotrexate for rheumatoid arthritis and psoriasis. Epinephrine for anaphylactic shock. Sumatriptan for acute migraine & cluster headache. Naloxone for respiratory depression with opioids abusers. Hydrocortisone for adrenal crisis. Midazolam for seizures like epilepsy crisis. Apormophine for off period in Parkinson.
We are seeking dossiers in the therapeutic areas of Cardio, Metabolic, Respiratory, Oncology, Aesthetics & CNS with Zone IV.b stability for ASEAN markets.
Generic to Zytiga/Janssen Cilag
Valganciclovir EU/ROW dossier available for licensing from leading generic producer.
Two new crystalline forms of canagliflozin – including anhydrate and octanol solvate – have been discovered and patented (CN 103936726 A). They show pharmaceutically developable properties.
We are seeking opportunities to sell modified release preparations in the UK.
We have sildenafil citrate tablets – 50mg and 100mg – for which we hold the MA in Germany and Spain. We would be interested to explore any out-licensing opportunity in the area of finished product supply or dossier for the same.
Multaq is the first anti-arrhythmia drug approved since amiodarone was approved in 1985. We have developed a non-infringing generic formulation.
Generic to Bifril and Bifrizide from Menarini
Generic to Novalgin from Sanofi.
Generic to Omacor/Abbott. Omega-3 90 ethyl esters 1000mg soft gel capsules (460mg EPA/380mg DHA).
Generic to Vesicare/Astellas. Solifenacin succinate 5mg and 10mg film-coated tablets.
Generic to Actonel/Sanofi. Risedronate sodium 35mg and 75mg film-coated tablets.
We are seeking dossiers for pharmaceutical products with zone IV a / b stability and bioequivalence studies meeting the requirements of the MENA region
Generic to Lyrica/Pfizer. Pregabalin 25mg/50mg/75mg/150mg/300mg hard gel capsules and 20mg/ml oral solution.
We require dossiers for a broad range of medicines for the EU, USA and MENA on a non-exclusive basis.
Athena have developed CTD dossiers on Oral Drug Delivery Products that we are looking to license out to partners who can receive products either in finished packs or bulk for local compression/encapsulation.
This is an extended release injection product that is being developed as an NDA in the USA and as an EU CTD MAA, as a low cost alternative to Invega Sustenna Injection Depot.
The product is a 30-day depot formulation being developed as an EU CTD MAA and as a USA NDA 505 (b)(2) that is non-infringing.
This is an extended release injection product that is being developed as an ANDA and as an EU CTD MAA.
The oral dispersible tablets are available in 125mg, 250mg and 500mg strengths.
The product is a 30-day depot formulation being developed as an EU CTD MAA.
This product is identical in every respect to Seretide Diskus. MA was granted in one EU country in 2013 and is launched. It is still available for license in some EU countries, and for all countries outside of Europe except the USA.
This product is highly similar to Humira and is fully documented, with stability according to EU requirements; with regulatory analytics according to the EU requirements; and, proof of comparability in a phase I human study. Phase III pK/PD comparative clinical studies in humans were completed in 2013.
This once-daily generic product treats attention deficit disorder (ADHD) and is available for license outside the USA including Europe. It is manufactured in USA FDA inspected facility and launched in the USA.
This product (100 and 400mg vials) is highly similar to Avastin and is fully documented, with comparability and stability according to EU requirements; with regulatory analytics according to EU requirements; and, proof of comparability in a phase I pK/PD comparative clinical study in humans.
This product is highly similar to MabThera and is fully documented, with stability and comparability according to EU and USA requirements; and, proof of comparability with phase I and phase III pK/PD comparative clinical studies in humans.
Prevention and treatment of vitamin D deficiency in the elderly.
Vasodilatory for angina treatment.
Lipstick 3g - 5% aciclovir.
Alkalon offers a range of finished product formulations and is seeking partnership opportunities worldwide.
2 and 4 mg available in several flavours.
Our Nicotine Polacrilex Chewing Gum portfolio is based on a high quality dossier and has received MA's in several EU countries.